KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evolent Health (EVH) Shares Outstanding (2016 - 2025)

Evolent Health (EVH) has 9 years of Shares Outstanding data on record, last reported at $113.1 million in Q2 2023.

  • For Q2 2023, Shares Outstanding rose 23.38% year-over-year to $113.1 million; the TTM value through Jun 2023 reached $113.1 million, up 23.38%, while the annual FY2022 figure was $101.5 million, 11.84% up from the prior year.
  • Shares Outstanding reached $113.1 million in Q2 2023 per EVH's latest filing, roughly flat from $112.6 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $113.1 million in Q2 2023 and bottomed at $706000.0 in Q2 2019.
  • Average Shares Outstanding over 5 years is $81.8 million, with a median of $87.0 million recorded in 2021.
  • Peak YoY movement for Shares Outstanding: crashed 99.1% in 2019, then soared 12046.88% in 2020.
  • A 5-year view of Shares Outstanding shows it stood at $84.6 million in 2019, then increased by 1.54% to $85.9 million in 2020, then grew by 5.66% to $90.8 million in 2021, then grew by 11.84% to $101.5 million in 2022, then grew by 11.41% to $113.1 million in 2023.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding were $113.1 million in Q2 2023, $112.6 million in Q1 2023, and $101.5 million in Q4 2022.